Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Opportunities and Challenges in Precision Neurotherapeutics.

PMID: 41543941 ·

Lilianne R Mujica-Parodi, Dost Öngür, R Mark Richardson

JournalAnnual review of biomedical engineering
Year
PMID41543941

Abstract

Precision neurotherapeutics represents a transformative paradigm shift from standardized "one-size-fits-all" treatments of neurological, neurodegenerative, and/or psychiatric disorders toward individualized interventions that leverage patient-specific biological, behavioral, and physiological characteristics. Traditional neurotherapeutic approaches achieve modest response rates of 30-60% for first-line treatments, necessitating personalized strategies that account for individual differences in g

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.